BRPI0410763A - derivados de triazol como inibidores de fator xa - Google Patents

derivados de triazol como inibidores de fator xa

Info

Publication number
BRPI0410763A
BRPI0410763A BRPI0410763-2A BRPI0410763A BRPI0410763A BR PI0410763 A BRPI0410763 A BR PI0410763A BR PI0410763 A BRPI0410763 A BR PI0410763A BR PI0410763 A BRPI0410763 A BR PI0410763A
Authority
BR
Brazil
Prior art keywords
factor
compounds
formulae
chem
factor viia
Prior art date
Application number
BRPI0410763-2A
Other languages
English (en)
Inventor
Marc Nazare
Volker Laux
Armin Bauer
Michael Wagner
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0410763A publication Critical patent/BRPI0410763A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"DERIVADOS DE TRIAZOL COMO INIBIDORES DE FATOR Xa". A presente invenção diz respeito aos compostos das fórmulas I e II, em que R¬ 0¬; R¬ 1¬; R¬ 2¬; R¬ 3¬; Q; J¬ 1¬; J¬ 2¬; J¬ 3¬; J¬ 4¬; J¬ 5¬; V; G e M têm os significados indicados nas reivindicações. Os compostos das fórmulas I e II são compostos farmacologicamente ativos valiosos. Eles apresentam um efeito anti-trombótico forte e são adequados, por exemplo, para a terapia e profilaxia de distúrbios cardiovasculares como doenças tromboembólicas ou restenoses. Eles são inibidores reversíveis das enzimas de coágulo sanguíneo fator Xa (FXa) e/ou fator VIIa (FVIIa), e podem em geral ser aplicados em condições em que uma atividade indesejada de fator Xa e/ou fator VIIa está presente ou para a cura ou prevenção da qual uma inibição de fator Xa e/ou fator VIIa é intencionada. A invenção diz respeito além disso aos processos para a preparação de compostos das fórmulas I e II, seu uso, em particular como ingredientes ativos em farmacêuticos, e preparações farmacêuticas os compreendendo.
BRPI0410763-2A 2003-05-19 2004-05-05 derivados de triazol como inibidores de fator xa BRPI0410763A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011309A EP1479679A1 (en) 2003-05-19 2003-05-19 Triazole-derivatives as factor Xa inhibitors
PCT/EP2004/004752 WO2004101555A1 (en) 2003-05-19 2004-05-05 TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
BRPI0410763A true BRPI0410763A (pt) 2006-08-01

Family

ID=33040956

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410763-2A BRPI0410763A (pt) 2003-05-19 2004-05-05 derivados de triazol como inibidores de fator xa

Country Status (12)

Country Link
EP (2) EP1479679A1 (pt)
JP (1) JP4608495B2 (pt)
AT (1) ATE394396T1 (pt)
AU (1) AU2004238498B2 (pt)
BR (1) BRPI0410763A (pt)
CA (1) CA2526082C (pt)
DE (1) DE602004013577D1 (pt)
IL (1) IL171843A (pt)
MX (1) MXPA05012058A (pt)
PE (1) PE20050154A1 (pt)
TW (1) TW200503694A (pt)
WO (1) WO2004101555A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
SI2000465T1 (sl) 2006-03-24 2011-04-29 Eisai R&D Man Co Ltd Derivat triazolona
UA105758C2 (uk) * 2007-07-19 2014-06-25 Х. Луннбек А/С 5-членні гетероциклічні аміди та споріднені сполуки
US7807690B2 (en) 2007-09-21 2010-10-05 Eisai R&D Management Co., Ltd. 2,3-dihydro-iminoisoindole derivatives
RU2017144535A (ru) * 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
KR20150132148A (ko) 2013-03-15 2015-11-25 베르선 코포레이션 세린 프로타아제 억제제로서의 다중 치환된 방향족 화합물
US9951025B2 (en) * 2013-03-15 2018-04-24 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
EA031746B1 (ru) 2013-03-15 2019-02-28 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
KR20170048410A (ko) 2014-09-17 2017-05-08 베르선 코포레이션 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
MX2017011000A (es) 2015-02-27 2017-10-20 Verseon Corp Compuestos de pirazol sustituidos como inhibidores de serina proteasa.
EP3759095A1 (en) 2018-03-01 2021-01-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP1042299A1 (en) * 1997-12-22 2000-10-11 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1226123A1 (en) * 1999-11-03 2002-07-31 Du Pont Pharmaceuticals Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
JP4608495B2 (ja) 2011-01-12
CA2526082A1 (en) 2004-11-25
CA2526082C (en) 2012-07-24
DE602004013577D1 (de) 2008-06-19
MXPA05012058A (es) 2006-06-23
AU2004238498A1 (en) 2004-11-25
EP1628971B1 (en) 2008-05-07
AU2004238498B2 (en) 2010-07-22
WO2004101555A1 (en) 2004-11-25
TW200503694A (en) 2005-02-01
EP1628971A1 (en) 2006-03-01
IL171843A (en) 2010-12-30
JP2006528941A (ja) 2006-12-28
EP1479679A1 (en) 2004-11-24
PE20050154A1 (es) 2005-04-29
ATE394396T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
BRPI0410466A (pt) derivados de indol como inibidores de fator xa
BRPI0410430A (pt) derivados de indazol como inibidores de fato xa
PT1349847E (pt) Novos derivados de oxibenzamidas como inibidores do factor xa
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
WO2003044014A8 (en) Indole-2-carboxamides as factor xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
WO2005085239A3 (en) PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
WO2004050636A3 (en) IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2387 DE 04-10-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.